J. Goldman & Co LP

Position in ANNX — Annexon, Inc.

CIK 1412741 NEW YORK, NY

Back to ANNX Full portfolio

Position in ANNX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$662,622

-$283,704 QoQ

Shares Held

116,046

-32.1% QoQ

Ownership

0.057%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

#88

of 216 holders

Holding Since

Mar 2024

6 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in ANNX Over Time

Shares Held

Position Value (USD)

Derivatives in ANNX

reported options exposure · as of Jun 30, 2024

CallValue

$793,800

CallShares

162,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

J. Goldman & Co LP holds $154,729,761 across 52 Biotechnology names. ANNX ranks #40 (0.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	COGT	Cogent Biosciences, Inc.	637,994	$24,690,367
2	ALNY	Alnylam Pharmaceuticals, Inc.	38,698	$11,649,258
3	CAPR	Capricor Therapeutics, Inc.	427,321	$10,289,889
4	MGTX	MeiraGTx Holdings plc	601,972	$8,132,641
5	ARDX	Ardelyx, Inc.	1,579,828	$8,057,122
6	URGN	UroGen Pharma Ltd.	212,775	$7,830,120
7	VRTX	Vertex Pharmaceuticals Inc / Ma	12,311	$6,115,243
8	ELVN	Enliven Therapeutics, Inc.	112,129	$5,690,546

All Filings in ANNX

Export CSV

6 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$662,622	116,046	-32.1%	Shares	Sole	2026-08-14
2026-03-31	$946,326	170,817	-82.8%	Shares	Sole	2026-05-15
2025-12-31	$4,988,850	993,795	-10.2%	Shares	Sole	2026-02-17
2025-09-30	$3,376,353	1,107,001	+7446.0%	Shares	Sole	2025-11-14
2024-06-30	$793,800	162,000	—	Call	Sole	2024-08-14
2024-03-31	$105,183	14,670	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.